Revelation Biosciences Reports Q3 2025 Financial Results and Groundbreaking PRIME Study Data

Revelation Biosciences reported Q3 2025 financial results, with $12.7 million in cash and cash equivalents, up from $6.5 million at the end of 2024. The company's net cash used for operating activities was $6.3 million for the nine months ended September 30, 2025, compared to $14.6 million for the same period in 2024. Revelation also announced positive top-line results from the PRIME clinical study and received $9.6 million in gross proceeds from a warrant inducement in September 2025.